Cargando…
Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis
Since cells in solid tumors divide less rapidly than cells in the bone marrow or cells of the immune system, mitotic inhibitors often cause severe side effects when used for treatment of diseases like prostate cancer and breast cancer. One approach to overcome this problem involves attempts at devel...
Autores principales: | Zimmermann, Tomas, Christensen, Søren Brøgger, Franzyk, Henrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100299/ https://www.ncbi.nlm.nih.gov/pubmed/29914143 http://dx.doi.org/10.3390/molecules23061463 |
Ejemplares similares
-
Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics
por: Isaacs, John T., et al.
Publicado: (2021) -
Targeting Toxins toward Tumors
por: Franzyk, Henrik, et al.
Publicado: (2021) -
Scalable Synthesis of (−)-Thapsigargin
por: Chu, Hang, et al.
Publicado: (2016) -
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
por: Mahalingam, D, et al.
Publicado: (2016) -
Cell death induced by the ER stressor thapsigargin involves death receptor 5, a non-autophagic function of MAP1LC3B, and distinct contributions from unfolded protein response components
por: Lindner, Paula, et al.
Publicado: (2020)